Today’s Stock On Watch: Can Retrophin Inc’s Tomorrow be Different? The Stock Declines Again

Today's Stock On Watch: Can Retrophin Inc's Tomorrow be Different? The Stock Declines Again

The stock of Retrophin Inc (NASDAQ:RTRX) is a huge mover today! About 381,323 shares traded hands. Retrophin Inc (NASDAQ:RTRX) has risen 37.29% since April 18, 2016 and is uptrending. It has outperformed by 32.86% the S&P500.
The move comes after 8 months negative chart setup for the $764.80M company. It was reported on Nov, 18 by Barchart.com. We have $18.30 PT which if reached, will make NASDAQ:RTRX worth $61.18M less.

Retrophin Inc (NASDAQ:RTRX) Ratings Coverage

Out of 3 analysts covering Retrophin (NASDAQ:RTRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Retrophin has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock of Retrophin Inc (NASDAQ:RTRX) earned “Mkt Outperform” rating by JMP Securities on Monday, November 2. BMO Capital Markets initiated Retrophin Inc (NASDAQ:RTRX) on Tuesday, April 12 with “Outperform” rating. As per Wednesday, August 12, the company rating was downgraded by Zacks.

According to Zacks Investment Research, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.”

Insitutional Activity: The institutional sentiment increased to 1.63 in 2016 Q2. Its up 0.33, from 1.3 in 2016Q1. The ratio improved, as 15 funds sold all Retrophin Inc shares owned while 29 reduced positions. 12 funds bought stakes while 45 increased positions. They now own 38.66 million shares or 4.59% more from 36.97 million shares in 2016Q1.
Teachers holds 0.01% of its portfolio in Retrophin Inc (NASDAQ:RTRX) for 234,444 shares. Blackrock Advsr Llc holds 65,252 shares or 0% of its portfolio. The Pennsylvania-based Turner Investments L P has invested 0.5% in Retrophin Inc (NASDAQ:RTRX). Blackrock Japan Limited reported 443 shares or 0% of all its holdings. Savings Bank Of Ny Mellon holds 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX) for 522,706 shares. Rock Springs Capital Mgmt Limited Partnership holds 521,400 shares or 0.69% of its portfolio. Teacher Retirement Sys Of Texas accumulated 4,434 shares or 0% of the stock. California State Teachers Retirement Sys has 75,938 shares for 0% of their US portfolio. Blackrock Investment Mngmt Limited Liability Corporation last reported 0% of its portfolio in the stock. Nationwide Fund accumulated 23,344 shares or 0% of the stock. Jpmorgan Chase And has invested 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Lombard Odier Asset Management (Usa) Corp has invested 2.34% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Broadfin Cap Limited holds 4.61% or 2.66M shares in its portfolio. Aqr Capital Mgmt Llc accumulated 0% or 86,775 shares. Consonance Cap Mgmt L P, a New York-based fund reported 2.70 million shares.

Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 2 selling transactions for $297,343 net activity. Shih Alvin also sold $142,059 worth of Retrophin Inc (NASDAQ:RTRX) shares.

More news for Retrophin Inc (NASDAQ:RTRX) were recently published by: Fool.com, which released: “Why Shares of Retrophin Inc Are Soaring Today” on September 07, 2016. Fool.com‘s article titled: “Why Retrophin Inc was Down Today” and published on February 10, 2016 is yet another important article.

RTRX Company Profile

Retrophin, Inc. (Retrophin), incorporated on February 7, 2008, is a biopharmaceutical company. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Firm sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. The Company’s Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. The Company’s Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment